Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics’ U.S. subsidiary (Samsung Biologics America) has updated the acquisition amount to approximately KRW 521.6B and finalized the scheduled acquisition date as March 31, 2026, for acquiring a 100% stake in Human Genome Sciences to secure a U.S. drug substance manufacturing facility.
📊 [Key Disclosure Details & Financial Summary]
- Original Disclosure Date: 2025-12-22
- Amendment Date: 2026-03-31
- Reason for Amendment: Amendment due to finalization of the scheduled acquisition date and transaction amount
- Comparison of Key Acquisition Terms:
- Acquisition Amount:
- Before Amendment: KRW 413,616,000,000 (USD 280,000,000)
- After Amendment: KRW 521,552,263,617 (USD 353,068,144.88, Increased by USD 73,068,144.88)
- Ratio to Parent Total Assets:
- Before Amendment: 2.39% (Based on Samsung Biologics FY2024 consolidated total assets of KRW 17,336,296,349,511)
- After Amendment: 3.01% (Based on Samsung Biologics FY2024 consolidated total assets of KRW 17,336,296,349,511)
- Scheduled Acquisition Date:
- Before Amendment: Unconfirmed (Pending regulatory and external procedures)
- After Amendment: 2026-03-31 (Finalized scheduled acquisition date)
- Acquisition Amount:
- Target Company:
- Company Name & Nationality: Human Genome Sciences Inc. (USA)
- Total Shares Issued & Acquired: 800 shares (100% equity stake)
- Core Business: Pharmaceutical manufacturing (Holds U.S. drug substance manufacturing facility acquired from GSK)
- Subsidiary Information:
- Subsidiary Name: Samsung Biologics America, Inc. (100% owned subsidiary)
- CEO: Yong-Hwan Jin
- Other Key Notes:
- Breakdown of Consideration: Out of the final acquisition value of USD 353,068,144.88, USD 73,068,144.88 represents consideration for inventory and raw materials transferred, while the net facility and equity valuation stands at USD 280,000,000.
- Applied Exchange Rate: FX rate of USD/KRW 1,477.20 as of December 19, 2025.
- Purpose: Acquiring local U.S. manufacturing assets to respond to long-term regional demand.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Transaction Closing Based on Finalized Scheduled Acquisition Date
This filing is a correction disclosure reflecting the adjusted settlement amount and the finalized scheduled acquisition date for acquiring a U.S. manufacturing facility via a subsidiary. Confirming whether the actual closing and transfer procedures were completed as of the finalized scheduled acquisition date (March 31, 2026) is important for verifying the final execution of the transaction. Details can be verified in upcoming periodic reports and subsequent disclosures.
📢 Disclaimer & Source Notice
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Disclaimer: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
